🇺🇸 Calcipotriene/betamethasone in United States

38 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Diarrhoea — 7 reports (18.42%)
  2. Psoriasis — 7 reports (18.42%)
  3. Drug Ineffective — 5 reports (13.16%)
  4. Covid-19 — 3 reports (7.89%)
  5. Headache — 3 reports (7.89%)
  6. Nausea — 3 reports (7.89%)
  7. Pain In Extremity — 3 reports (7.89%)
  8. Sinusitis — 3 reports (7.89%)
  9. Atrial Fibrillation — 2 reports (5.26%)
  10. Eye Pain — 2 reports (5.26%)

Source database →

Other Dermatology approved in United States

Frequently asked questions

Is Calcipotriene/betamethasone approved in United States?

Calcipotriene/betamethasone does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Calcipotriene/betamethasone in United States?

Derm Research, PLLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.